Recursion Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
RXRX
CUSIP
75629V104
All holders as of
Q2 2026
Type
Equity
Class
CL A
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 75629V104 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 8.5% 7/29/2026
Event 6/30/2026
ARK Investment Management LLC 13G/A
7.3% 2/3/2026
Event 12/31/2025
State Street Corp 13G 6.6% 8/7/2026
Event 6/30/2026
Vanguard Portfolio Management LLC 13G 6.0% 7/31/2026
Event 6/30/2026
Yohan Kim 13G 5.9% 4/4/2025
Event 4/4/2025
Vanguard Capital Management LLC 13G 5.1% 7/31/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Baillie Gifford & Co 13G/A 4.6% 2/5/2026
Event 12/31/2025
RA Capital Management, L.P. 13G/A
2.0% 2/14/2025
Event 12/31/2024
Mubadala Investment Co PJSC 13D/A
1.4% 12/23/2025
Event 11/20/2024
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 84 7.25 M $29.9 M
2026 Q2 366 364 M $1.89 B
2026 Q1 355 336 M $1.03 B
2025 Q4 358 325 M $1.33 B
2025 Q3 355 328 M $1.60 B
2025 Q2 365 312 M $1.58 B
2025 Q1 366 308 M $1.63 B
2024 Q4 346 305 M $2.06 B
2024 Q3 288 266 M $1.76 B
2024 Q2 290 255 M $1.91 B
2024 Q1 268 218 M $2.17 B
2023 Q4 214 211 M $2.08 B
2023 Q3 212 152 M $1.17 B
2023 Q2 166 128 M $953 M
2023 Q1 168 126 M $842 M
2022 Q4 152 132 M $1.02 B
2022 Q3 152 114 M $1.21 B
2022 Q2 138 106 M $861 M
2022 Q1 133 95.1 M $681 M
2021 Q4 133 94.6 M $1.62 B
2021 Q3 92 54.9 M $1.26 B
2021 Q2 80 47.0 M $1.71 B
2021 Q1 1 30.0 $1.00 k
2020 Q4 1 30.0 $1.00 k
2020 Q3 1 30.0 $1.00 k
2020 Q2 1 30.0 $1.00 k
2020 Q1 1 30.0 $1.00 k
2019 Q4 1 30.0 $1.00 k
2019 Q3 1 30.0 $1.00 k
2019 Q2 1 30.0 $1.00 k
2019 Q1 1 30.0 $1.00 k